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http://dx.doi.org/10.1016/j.jaci.2015.10.045Background: The Gly-to-Arg substitution at the 16 position
(rs1042713) in the b2-adrenoceptor gene (ADRB2) is associated
with enhanced downregulation and uncoupling of b2-receptors.
Objectives: We sought to undertake a meta-analysis to test the
hypothesis that there is an interaction between the A allele of
rs1042713 (Arg16 amino acid) and long-acting b-agonist
(LABA) exposure for asthma exacerbations in children.
Methods: Children with diagnosed asthma were recruited in 5
populations (BREATHE, Genes-Environments and Admixture
in Latino Americans II, PACMAN, the Paediatric Asthma Gene
Environment Study, and the Pharmacogenetics of Adrenal
Suppression with Inhaled Steroid Study). A history of recent
exacerbation and asthma treatment was determined from
questionnaire data. DNA was extracted, and the Gly16Arg
genotype was determined.
Results: Data from 4226 children of white Northern European
and Latino origin were analyzed, and the odds ratio for
exacerbation increased by 1.52 (95% CI, 1.17-1.99; P 5 .0021)
for each copy of the A allele among the 637 children treated with
inhaled corticosteroids (ICSs) plus LABAs but not for treatment
with ICSs alone (n 5 1758) or ICSs plus leukotriene receptor
antagonist (LTRAs; n 5 354) or ICSs plus LABAs plus LTRAs
(n 5 569).
Conclusions: The use of a LABA but not an LTRA as an ‘‘add-
on controller’’ is associated with increased risk of asthma
exacerbation in children carrying 1 or 2 A alleles at rs1042713.
Prospective genotype-stratified clinical trials are now required
to explore the potential role of rs1042713 genotyping for
personalized asthma therapy in children. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
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tion, therapeutics
Asthma is a common condition in children in which there is
heterogeneity in response to treatment with inhaled corticoste-
roids (ICSs), long-acting b-agonists (LABAs), and leukotriene
receptor antagonists (LTRAs).1,2 Some of this heterogeneity
might reflect genetic variations within the population, and vari-
ants in the b2-adrenoceptor gene (ADRB2) have been associated
with increased risk for symptoms.3-5 Of particular interest is the
single nucleotide polymorphism (SNP) rs1042713, a Gly-to-
Arg amino acid substitution at position 16 of the ADRB2 gene
that has been associated with differences in pulmonary function1
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The underlying mechanism of enhanced downregulation and un-
coupling of b2-receptors is thought to reflect an altered response
to SABAs and LABAs.
Although the SNP rs1042713 appears to alter physiologic and
clinical responses to SABAs and LABAs in pediatric popula-
tions, the clinical relevance of this association remains unclear.
In 2 clinical trials there was no evidence for an association
between the A allele of rs1042713 (Arg16 amino acid) and
increased symptom scores.1,7 There is inconsistent evidence
from observational studies that this SNP might be relevant to
exacerbations. In children the homozygous G/G genotype of
rs1042713 has been linked to increased risk for hospitaliza-
tion,10 reduced bronchodilator response to SABAs,9 prolonged
stay in the hospital,11 and intensive care unit stay12 after presen-
tation with acute asthma, whereas the heterozygous genotype of
rs1042713 has been linked to increased risk for intubation for
acute asthma.13 Two other groups have observed associations
between the A/A genotype of rs1042713 and increased exacer-
bations among those treated with LABAs,3,4 but this was not
confirmed in a third population.14 These studies have also
observed increased exacerbation risk3 and poorer asthma con-
trol4 among those children homozygous for A/A for the SNP
rs1042713 receiving ICSs (but not LABAs). In one study3 there
was evidence that concomitant LTRA treatment might negate
any increased risk for exacerbation associated with LABA treat-
ment, whereas those children who are homozygous for Arg16
had better asthma outcomes when treated with LTRAs rather
than LABAs in addition to ICSs.15 Prospective studies under-
taken in adult populations have found no evidence for LABA
treatment being associated with adverse outcomes when added
to ICS treatment.16-18
To better understand the interactions between the SNP
rs1042713 of ADRB2 and asthma treatment, we undertook a
meta-analysis of results from 5 previously described popula-
tions.19 Our hypothesis was that there is an interaction between
the A allele of rs1042713 (Arg16 amino acid) and treatment
with LABAs but not LTRAs for asthma exacerbation risk and
that this risk might be further increased by exposure to daily
SABAs.METHODS
Study design
Asthmatic children were recruited to 5 cross-sectional studies (BREATHE,
Genes-Environments and Admixture in Latino Americans II [GALA II], thePaediatric AsthmaGene Environment Study [PAGES], PACMAN, and PASS).
The BREATHE and PAGES populations were recruited from primary and
secondary care in Scotland, the PACMAN population was recruited from
children attending community pharmacies in The Netherlands, GALA II
recruited children in the United States and Puerto Rico who had 4 Latino
grandparents, and PASS recruited children with asthma who had adrenal
suppression testing in 25 hospitals across the United Kingdom. Further details
of the study population’s recruitment are presented in the Methods section in
this article’s Online Repository at www.jacionline.org. DNA was extracted
from saliva or blood, and the genotypes for rs1042713 were determined.
The primary outcome was asthma exacerbation (with reference to 6 months
in BREATHE, PAGES, and PASS and 12 months in GALA II and PACMAN).
Asthma treatment was categorized as follows: (1) as-required SABA but no
preventer treatment, (2) ICS monotherapy plus as-required SABA, (3) ICS
and LABA plus as required SABA, (4) ICS and LTRA plus as required
SABA, and (5) ICS, LABA and LTRA plus as required SABA. As defined
previously,5 use of as required SABAs was categorized as at least once daily
or less frequently. Approval was obtained from medical research ethics com-
mittees from each institute before recruitment. All participants provided ver-
bal assent, and parents or participants provided written consent, as
appropriate.Definitions of exacerbation
For BREATHE and PAGES, the definition of exacerbation was at least 1 of
the following in the previous 6 months in the context of asthma symptoms:
hospital admission, course of oral steroids, or absence from school. For GALA
II, an exacerbation was defined as at least 1 of the following during the
previous 12 months: oral corticosteroid rescue treatment, hospitalization, or
need to seek emergency asthma care. For PACMAN, an exacerbation was
defined as an asthma-related visit to the emergency department, prescription
of a course of oral steroids in the past 12 months, or both. The definition of
exacerbation for PASS was at least 1 course of rescue oral steroids in the
previous 6 months.DNA collection, extraction, and analysis
For BREATHE, PACMAN, and PAGES, saliva was collected in commer-
cially available pots (Oragene; DNA Genotek, Ontario, Canada), DNA was
prepared with the Qiagen DNeasy 96 Kit (Qiagen, Hilden, Germany), and
genotypes were determined in the Dundee laboratory by using TaqMan-based
allelic discrimination assays on an ABI 7700 Sequence Detection System
(Applied Biosystems, Foster City, Calif), as described previously.3 For GALA
II, DNAwas extracted from whole blood, and the Axiom LAT1 array (World
Array 4; Affymetrix, Santa Clara, Calif) was used to determine genome-wide
genotype data, as described elsewhere.20 For PASS, the Illumina Human
OmniExpressExome-8 v1.0 chip (Illumina, San Diego, Calif) was used for
genotyping.Statistical analysis
The primary outcome was recent exacerbation, and this was related to
genotype in logistic models. An additive model3 was used (ie, a gene/dosage
effect for the A allele [Arg16 amino acid]), which adjusted for confounders
(ie, sex, age, and second-hand smoke exposure3). Each population was strat-
ified by treatment, and risk for exacerbation per genotype was calculated in
each treatment group. Daily SABA use was recorded for BREATHE, PAC-
MAN, and PAGES, and here an interaction was sought for SABA
treatment 3 genotype. Regression analyses in GALA II included the
same covariates as in the other studies, but additionally, we included esti-
mates of global African and Native American genetic ancestry to avoid
confusion because of population stratification. Standard statistical software
was used (SPSS version 22.0.0.1; SPSS, Chicago, Ill). The meta-analysis
of data from the 5 populations was performed by using a fixed-effect (in-
verse variance–weighted) model in which the effect size estimates, b-coef-
ficients, are weighted by their estimated SEs by using GWAMA software.21
We estimated the power of the study to detect associations with
TABLE I. Comparison of details of children in each of the 5 study populations
BREATHE (n 5 1210) GALA II (n 5 1171) PACMAN (n 5 760) PAGES (n 5 695) PASS (n 5 390)
Male sex, % (no.) 60 (725) 58 (676) 63 (478) 57 (399) 56 (172)
Exposed to tobacco smoke at
home, % (no.)
35 (424) 21 (242) 14 (108) 21 (146) 36 (108)
Mean age, y (SD) 9.7 (3.8) 11.9 (2.7) 8.7 (2.3) 9.8 (3.7) 11.1 (4.0)
Recent exacerbation, % (no.) 44 (536) 65 (763) 10 (76) 47 (323) 75 (295)
Ethnicity, %
White No data 0 90* (681/753) 93 (358/384) 99 (388/390)
Hispanic 100 0.4 (3/753) 0 0
African 0 1 (8/753) 0 0
Other (including mixed) 0 8.6 (61/753) 7 (26/384) 1 (2/390)
Minor allele frequency{ 0.37 0.45 0.41 0.37 0.38
rs1042713 genotype, % (no.)
A/A (Arg/Arg) 15 (175) 20 (234) 15 (115) 14 (96) 16 (61)
A/G (Arg/Gly) 43 (515) 49 (579) 51 (388) 46 (321) 43 (169)
G/G (Gly/Gly) 43 (520) 31 (358) 34 (257) 40 (278) 41 (160)
Treatment group, % (no.)
SABA alone 18 (218) 42 (490) 10 (73) 7 (51) 0
ICS 58 (698) 24 (283) 63 (476) 40 (273) 7 (28)
ICS plus LABA 11 (138) 10 (122) 19 (147) 19 (134) 33 (96)
ICS plus LTRA 5 (65) 15 (177) 3 (23) 9 (65) 8 (24)
ICS plus LABA plus LTRA 8 (91) 9 (99) 5 (41) 24 (169) 59 (230)
With daily SABA dosing, % (no.) 21 (250)  49 (364) 30 (209) 
*Dutch, Moroccan, and Turkish ethnicities were considered white in PACMAN.
Ethnicity data were not available for all participants in PAGES.
Daily SABA status was not determined in GALA II and PASS.
{Minor allele frequency 5 Frequency of minor allele homozygous genotype 1 (Frequency of heterozygous genotype)/2.
TABLE II. OR for exacerbation per copy of the A allele (Arg16 amino acid)
Treatment
group
OR (95% CI) for exacerbation per A allele (referenced to none)
BREATHE GALA II PACMAN PAGES PASS
Results from
all cohorts
combined
Results for
all cohorts
except GALA II
SABA alone 0.87 (0.54-1.40),
n 5 218
1.08 (0.81-1.43),
n 5 490
1.07 (0.06-20.2),
n 5 73
0.71 (0.18-2.80),
n 5 51
* 1.01 (0.79-1.28),
n 5 832,
P 5 .95
0.85 (0.55-1.33),
n 5 342,
P 5 .49
ICS alone 1.15 (0.92-1.43),
n 5 698
1.12 (0.78-1.62),
n 5 283
0.83 (0.53-1.31),
n 5 476
1.17 (0.80-1.71),
n 5 273
4.81 (0.79-29.33),
n 5 28
1.11 (0.95-1.31),
n 5 1758,
P 5 .18
1.11 (0.94-1.33),
n 5 1475,
P 5 .22
ICS1LABA 1.52 (0.92-2.50),
n 5 138
2.07 (1.03-4.16),
n 5 122
2.54 (1.06-6.06),
n 5 147
1.29 (0.76-2.19),
n 5 134
1.21 (0.68-2.14),
n 5 96
1.52 (1.17-1.99),
n 5 637,
P 5 .0021
1.44 (1.08-1.93),
n 5 515,
P 5 .01
ICS1LTRA 1.86 (0.85-4.08),
n 5 65
1.26 (0.79-2.02),
n 5 177
2.10 (0.43-10.2),
n 5 23
0.69 (0.34-1.39),
n 5 65
0.31 (0.08-1.18),
n 5 24
1.11 (0.80-1.55),
n 5 354,
P 5 .52
0.98 (0.61-1.56),
n 5 177,
P 5 .93
ICS1LABA
1LTRA
1.03 (0.54-1.96),
n 5 91
0.93 (0.36-2.39),
n 5 99
0.23 (0.04-1.46),
n 5 41
0.87 (0.52-1.45),
n 5 169
1.02 (0.70-1.48),
n 5 169
0.94 (0.73-1.22),
n 5 569,
P 5 .65
0.95 (0.72-1.24),
n 5 470,
P 5 .68
Results are from logistic regression models that adjusted for sex, age, and exposure to secondhand smoke at home.
*There were no children in PASS receiving SABAs alone.
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calculations provide the maximal power we could obtain from the meta-
analysis of the cohorts at a significance level of 5%. Odds ratios (ORs) of
1.2, 1.5, and 3 were selected based on initial results from the BREATHE
population. With the exception of the ICS1LTRA treatment group, all strata
were sufficiently powered to detect an OR of 1.5 or greater (see Table E1 in
this article’s Online Repository at www.jacionline.org). Forest plots were
generated with the package rmeta for R software. A P value of less than
.05 was assumed to be significant.RESULTS
Study subjects
Genotype, treatment, and exacerbation data were available for
4226 children, including 1210 from the BREATHE, 1171 from
GALA II, 760 from PACMAN, 695 from PAGES, and 390 from
PASS (Table I). The Gly16Arg polymorphism was in Hardy-
Weinberg equilibrium (HWE) for all cohorts with the exception
of BREATHE (exact test P 5 .012) considered as a whole, but
TABLE III. The proportion (percentage) of children with exacerbations stratified by treatment class and SNP rs1042713
Treatment group
BREATHE GALA II
AA AG GG AA AG GG
SABA alone 7/29 (24%) 28/101 (28%) 25/88 (28%) 57/92 (62%) 150/241 (62%) 88/157 (56%)
ICS alone 52/98 (53%) 121/296 (41%) 126/304 (41%) 43/62 (69%) 93/151 (62%) 46/70 (66%)
ICS1LABA 18/22 (82%) 25/55 (46%) 33/61 (54%) 25/30 (83%) 43/56 (77%) 23/36 (64%)
ICS1LTRA 8/11 (73%) 18/26 (69%) 15/28 (54%) 22/34 (65%) 59/81 (73%) 39/62 (63%)
ICS1LABA1LTRA 11/15 (73%) 23/37 (62%) 26/39 (67%) 13/16 (81%) 37/50 (74%) 25/33 (76%)
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(P 5 .624). The minor allele frequency for GALA II was higher
when compared with that of the 3 United Kingdom cohorts
(0.45 vs 0.37, P5 13 10210) and intermediate for the PACMAN
population. Regardless of treatment, across the 5 populations, the
additive model found an increased risk for exacerbation for each
copy of the A allele amounting to 1.11 (95% CI, 1.01-1.22;
P 5 .035, n 5 4226; see Table E2 in this article’s Online Repos-
itory at www.jacionline.org).Risk of exacerbation across maintenance treatment
groups
TheOR for exacerbation was 1.52 (95%CI, 1.17-1.99) for each
copy of the A allele among the 637 children treated with an ICS
plus a LABA (Table II). The risk for exacerbation was not
increased among other treatment groups (Table II). Table III pre-
sents the proportion of children with exacerbations stratified by
population, treatment, and genotype. The analysis for children
treated with an ICS plus a LABA had greater than 90% power
to detect an association with increased risk for exacerbation at a
significance level of 5% (see Table E1). An analysis of local Af-
rican ancestry at the Gly16Arg locus was undertaken in the
GALA II population to examine whether the number of chromo-
somes indicative of African ancestry at this locus was associated
with increased exacerbations. There was no association of local
African ancestry with exacerbations in GALA II in the overall
population (OR, 1.17; 95% CI, 0.89-1.53; P 5 .270) or in the
group of patients treated with an ICS plus a LABA (OR, 1.78;
95% CI, 0.58-5.49; P 5 .316).Risk of exacerbation in relation to SABA use
Among the 822 children in receipt of daily SABAs (including
56whowere not receiving ICSs, LABAs, or LTRAs), therewas no
evidence of increased risk in the additive model (OR, 1.01; 95%
CI, 0.79-1.31; see Table E3 in this article’s Online Repository at
www.jacionline.org). Among those children in receipt of an ICS
plus a LABA, there was no evidence of any additional increased
risk in relation to each A allele for exacerbations among those
receiving daily SABAs (see Table E4 in this article’s Online Re-
pository at www.jacionline.org).Asthma control scores and Arg16 homozygous
genotype
The risk for poorly controlled asthma (as evidence by an
Asthma Control Questionnaire 6 score >1.5) was increased
among A/A homozygotes prescribed ICSs only within thePACMAN cohort (OR, 2.15).4 Within the PAGES population,
63% (282/446) had poorly controlled asthma (as evidenced by a
Children’s Asthma Control Test score <20), and there was no in-
crease in risk for poor control for A/A homozygotes among any of
the treatment groups.DISCUSSION
Genetic epidemiology is complicated by inconsistent findings
between populations. Therefore replication of findings across
different populations is crucial to generalizing results.23 Associa-
tions between SNP rs1042713 and LABA and SABA treatment
have been previously reported in evaluations of the first 546 chil-
dren recruited to BREATHE3 and the first 597 recruited to PAC-
MAN4 (data from 1210 and 760 included in the present report,
respectively). However, the results of other studies in adults
were in apparent conflict with the above observations. This meant
that before this study, the important clinical question of whether
there is a need to progress to further randomized controlled trials
assessing benefit with testing for SNP rs1042713 in the clinical
setting had not been resolved. This study combined data from 5
cohorts of children with asthma fromwhite European andHispan-
ic/Latino populations to explore interactions between exposures
to different asthma medications and the SNP rs1042713 for risk
of asthma exacerbation.
We analyzed data from 4226 children and drew 3 conclusions.
First, among children exposed to ICS plus LABA treatment as
dual-combination therapy, there was a 52% increased risk for
exacerbation for each copy of the A allele. Second, the
interaction between the A allele and exposure to LABAs was
not present when LTRA treatment was also coprescribed as triple
therapy. Third, there was no evidence that daily SABA use in
addition to ICS plus LABA treatment was associated with any
increased further risk for exacerbation among children carrying
at least one A allele. The combined incidence of the A/G
heterozygous and A/A homozygous genotype is approximately
60%, and these observations implicate the SNP rs1042713 as an
important factor in the well-recognized heterogeneity of treat-
ment response in children with asthma.1,2 This study has estab-
lished the need for further prospective clinical trials in which
treatment is stratified by genotype to move these observations
into clinical practice to evaluate a more personalized approach
to treatment of children with poorly controlled asthma despite
treatment with ICSs.
We observed heterogeneity between populations for the
relationship between SNP rs1042713 and treatment with an ICS
plus LABA and risk for exacerbation, with the risk being highest
in GALA II and lowest in PASS. Although this study was not
designed to explain the variability between populations, therewas
PACMAN PAGES PASS
AA AG GG AA AG GG AA AG GG
0/10 (0%) 2/42 (5%) 0/21 (0%) 0/8 (0%) 5/23 (22%) 4/20 (20%) 0 0 0
6/76 (8%) 24/243 (10%) 19/157 (12%) 15/38 (40%) 33/122 (27%) 35/113 (31%) 1/2 (50%) 7/15 (47%) 2/11 (18%)
6/20 (30%) 3/73 (4%) 4/54 (7%) 11/18 (61%) 36/64 (56%) 25/52 (48%) 8/17 (47%) 25/41 (61%) 16/38 (42%)
1/5 (20%) 3/9 (33%) 1/0 (11%) 5/11 (46%) 16/27 (59%) 17/27 (63%) 2/5 (40%) 2/7 (29%) 10/12 (83%)
0/4 (0%) 3/21 (14%) 4/16 (25%) 14/21 (67%) 58/82 (71%) 47/66 (71%) 17/35 (49%) 58/101 (57%) 48/94 (51%)
TABLE III. (Continued)
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risk associated with the A allele and characteristics of the 5
populations; for example, the children inGALA II and PASSwere
comparable in terms of age, sex distribution, and exacerbation
rate. More children in PASS were in receipt of an ICS plus LABA
compared with those in GALA II, but the hypothesis that
exacerbation risk attributable to the A allele is lower for
populations in which LABA treatment is more prevalent is not
supported by observations in the PACMAN and PAGES pop-
ulations, where 19% in each received LABAs, but the exacerba-
tion risk associated with ICS plus LABA use was 2.54 and 1.29,
respectively. The heterogeneity between populations and within
populations1,2 might provide potential insight into the pharmaco-
genetic mechanism or mechanisms but also highlights the need
for stratified treatment in childhood asthma.
The minor allele frequency was substantially higher for
children in the GALA II population compared with those in the
3 United Kingdom populations, and as suggested by previous
work,18,24 we explored the possibility that the increased exacerba-
tion rate associated with the Arg16 allele in LABA-treated GALA
II subjects reflected the African ancestry associated with this
allele. In our adjustment for measures of ancestry for the analyses
of the Gly16Arg locus within the GALA II population, we did not
find significant evidence that African ancestry was relevant to the
positive correlation between minor allele frequency and preva-
lence of exacerbation; however, our analysis was underpowered,
and the 2-fold increase in risk detectedmight have been significant
had our sample size been larger. Our study was not designed to
explore how ethnic differencesmight be relevant to the pharmaco-
genetics or treatment response to LABAs, and unfortunately, there
were insufficient numbers of children with African ancestry in the
cohorts other than GALA II to further explore this intriguing hy-
pothesis, which merits focused research in the future.
The pharmacogenetics of LABAs and SABAs are notable for
the contrasting effects seen for the Gly16Arg locus on acute
versus chronic SABAs. There has been considerable consistency
in the observed effects of Gly16Arg on acute SABA response,
with many studies showing a similar direction of effect on
bronchodilation (favoring Arg16).6,7,11,25,26 A seemingly oppo-
site effect (favoring Gly16) was seen for chronic SABA exposure
and lung function and asthma control in the Beta Agonists in
Mild Asthma27 and Beta-Adrenergic Response by Genotype28
studies and another study by Taylor et al.29 The focus of the pre-
sent study was LABA therapy, but we found no evidence for
either daily SABA use or the combination of a daily SABA
plus LABA being linked to increased exacerbation risk for chil-
dren carrying the Arg16 allele. One interpretation of our findings
is that the LABA caused effective adrenoceptor blockade, and the
‘‘adverse’’ effect of LABA treatment had subsumed any‘‘benefit’’ of acute SABA treatment for individuals carrying an
Arg16 allele.
Although we find evidence here for response to LABA therapy
to be modified by the Gly16Arg locus in children, for adults, this
locus appears to have no effect on response to LABA therapy
based on large retrospective analyses and prospective genotype-
stratified clinical trials by Bleecker et al16 and Weschler et al.18
There is evidence that the Gly16 allele might be associated with
a bronchoprotective effect in association with LABA treat-
ment.18,30 The present study was not designed to explore the
apparent inconsistency between observations in adults and chil-
dren, but differences in response of children and adults to LABAs
are well recognized. The addition of a LABA to ICS treatment in
adults with poorly controlled asthma is accepted to be superior to
alternative treatments,31,32 but in children the evidence is that
LABAs are no more effective than addition of an LTRA or an in-
crease in ICS dose.1,33
In the literature there are apparently conflicting associations
reported between variants of the SNP rs1042713 and response to
treatment.3-6,9,11 One explanation for this heterogeneity is that the
earlier findings are based on relatively small single populations (ie,
which number less than 1000) and that a meta-analysis addresses
the potential for false-positive findings and/or associations, which
are idiosyncratic for one population. This meta-analysis confirms
previously reported increases in the risk for exacerbations among
Arg16 homozygotes in receipt of LABA treatment.3,4 The present
study did not replicate previously reported associations between
the homozygous genotype A/A and treatment with ICSs alone
and increased risk for exacerbation3 or poor asthma control,4 sug-
gesting the possibility of false-positive findings. Themagnitude of
risk for exacerbation associatedwith ICS andLABA treatment and
the A allele reported in the first 546 children recruited to the
BREATHE cohort3 is slightly reduced in the larger population
(2.1 vs 1.5) but remains significant across all 5 populations. The
5 populations included were heterogeneous for asthma outcomes,
and the results could be generalized toWestern European and His-
panic/Latino populations, but given the potential for different as-
sociations between rs1042713 and asthma treatment response
between different ethnic groups,26 our results might not be rele-
vant to all populations.
In our analysis we explored the possible additive effect of
treatment with daily SABAs and LABAs for exacerbations, and
we have previously reported that either treatment is associated
with increased exacerbations for the BREATHE population
among Arg/Arg homozygotes.5 When data were pooled, there
was no apparent additive effect of SABAs on LABA use for exac-
erbation risk for children with 1 or 2 Arg alleles. These results
should be treated with caution because, even with a relatively
large population, such as we present here, there were relatively
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the analysis was probably underpowered. There might be a
modest additive effect, which we were not able to detect.
The mechanism or mechanisms underlying the association
between the Arg16 allele and increased exacerbation in the
context of LABA treatment are thought to be mediated by
enhanced agonist-induced downregulation and receptor uncou-
pling, resulting in subsensitivity of response.34,35 Our novel
finding of no increased risk for exacerbation amongA/A homozy-
gotes in receipt of ICSs, LABAs, and LTRAs suggests that factors
other than ADRB2 downregulation are active because LABA
exposure in this group of children might be expected to downre-
gulate ADRB2. It is likely that LTRAsmerely confer an additional
anti-inflammatory effect in subjects exposed to LABAs, such that
in genetically susceptible patients it might be seen as a salutary
effect by counteracting the response to LABAs. Where the
LABA effect is negated (ie, in Arg/Arg), the additive effect of
LTRAs will be more evident compared with a setting in which
the LABA effect is more pronounced (ie, Gly/Gly), and the addi-
tive effect of LTRAwill be less evident. Indeed, in one study using
AMP challenge as the primary outcome, there was better protec-
tion with ICS1LABA1LTRA as triple therapy compared with
dual therapy with ICS1LABA, which was also mirrored by ef-
fects on exhaled nitric oxide levels and blood eosinophil counts,
suggesting that the apparent counteracting role of LTRAs might
arise from the additional anti-inflammatory effects of LTRAs.36
This study has a number of limitations that should be
considered when these results are interpreted. First, the associ-
ations described here do not imply causation, but the findings are
consistent with the results of a small genotype-stratified random-
ized controlled trial, which found favorable outcomes amongA/A
homozygotes taking LTRAs compared with LABAs over a period
of 12 months when used as add-on therapy to ICSs.15
Second, although we are able to be conclusive as to the nature
of the relationship between exposure to LABAs and A/A homo-
zygous genotype and exacerbation, we cannot exclude the
possibility that there might be a small additive relationship
between SABAs and LABAs for exacerbation. The relationship
between LABAs, SABAs, and exacerbations will always be a
challenge to study because frequent SABA treatment is an
indication for LABA therapy, but our findings suggest that the
magnitude of association with LABAs is greater than with
SABAs, which perhaps is not surprising given the potential effect
of more prolonged receptor occupancy conferred by LABAs than
SABAs, especially in genetically susceptible subjects.
Third, more detailed genotyping of the ADRB2 locus or haplo-
type analysis might have yielded additional insight into the rela-
tionship between genetic variations of ADRB2, but neither
genome-wide association study or haplotype data were available
for all cohorts.We focused on the SNP rs1042713 because there is
a large body of related literature, which indicates that this is asso-
ciated with outcomes for asthma treatment.
A fourth limitation is that we have assumed that treatment has
been assigned based on the same criteria, and it is possible that in
some cohorts, children with more severe asthma and at increased
risk for exacerbations might not have received LABA treatment,
but this would tend to underestimate the effect of the interaction
between LABA treatment and the SNP rs1042713 for
exacerbations.
A fifth limitation is that rare variants were not genotyped,
which could also have an effect on adverse events during LABAtherapy; however, these cohorts were not powered for a rare
variant analysis, and the rare variants identified by Ortega et al37
occurred on the background of Gly16 but not Arg16.
Finally, the Gly16Arg allele polymorphism frequency was not
in HWE for the whole BREATHE cohort, but the consistency of
the results across the cohorts suggests that the deviation within
this single cohort did not substantially influence the overall
results. Furthermore, Gly16Arg is an inconsistently replicated
and, at best, weak locus for asthma severity, and therefore it does
not seem plausible that selection for exacerbation (the primary
outcome and linked to asthma severity) in this study is the cause
for the deviation from HWE seen in the BREATHE cohort.
Because Gly16Arg is a better established pharmacogenetic locus,
a more plausible outcome that would influence deviations from
HWE is exacerbations or symptoms despite frequent SABA or
LABA use, but this represents a small percentage of the
BREATHE cohort (18% and 11%, respectively).
In conclusion, children with asthma receiving an ICS plus
LABAwere at 52% increased risk for exacerbation in the previous
6 to 12 months for each A allele (Arg16 amino acid) compared
with G/G homozygotes (Gly16/Gly16). Given that there are 1
million children in the United Kingdom with asthma, 10% of
these are prescribed LABAs,38 and 60% of these carry at least 1
Arg16 allele, there are approximately 60,000 children in the
United Kingdom today and approximately 25,000 in The
Netherlands whomight be at risk from the morbidity of exacerba-
tion, which is preventable by treatment with either no LABAs or
perhaps with the addition of an LTRA if genotyping of rs1042713
could be made available at the point of prescribing. Put another
way, and assuming that at least one third of the UK national health
care costs attributable to childhood asthma are due to urgent
care,39,40 stratified treatment might reduce the annual direct costs
to the United Kingdom National Health Service for the manage-
ment of childhood asthma exacerbations by 10% (ie, a 50% reduc-
tion in 60% of the population). Although there are no recent
published costs for the management of childhood asthma, costs
in the United States have been estimated at $791 per child per an-
num in 200540 and to total £150 million in the United Kingdom in
1997.41 Thus it is likely that stratified treatment in childhood
asthma will save tens of millions of pounds in direct health care
costs. Not all asthmatic patients who inherit an A allele will expe-
rience increased morbidity with LABA treatment, and this might
be explained by rare variants, perhaps at the same locus37;
pathway-related variation42; epigenetic mechanisms; or treat-
ment adherence.Key message
d Clinical trials are required to determine whether treat-
ment stratified by rs1042713 will reduce asthma exacer-
bation risk in children with 1 or 2 A alleles.REFERENCES
1. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez
FD, et al. Childhood Asthma Research and Education (CARE) Network of the
National Heart, Lung, and Blood Institute. Step-up therapy for children with un-
controlled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:
975-85.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
TURNER ET AL 72. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC,
et al. Characterization of within-subject responses to fluticasone and montelukast
in childhood asthma. J Allergy Clin Immunol 2005;115:233-42.
3. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Argi-
nine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asth-
matics taking regular salmeterol. Thorax 2006;61:940-4.
4. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppel-
man GH, et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation
in children with a reported use of long-acting beta2-agonists: results of the PAC-
MAN cohort. Pharmacogenomics 2013;14:1965-71.
5. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic
beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic
patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009;124:
1188-94.e3.
6. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between
genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in chil-
dren with and without a history of wheezing. J Clin Invest 1997;100:3184-8.
7. Silverman EK, Kwiatkowski DJ, Sylvia JS, Lazarus R, Drazen JM, Lange C, et al.
Family-based association analysis of beta2-adrenergic receptor polymorphisms in
the childhood asthma management program. J Allergy Clin Immunol 2003;112:
870-6.
8. Turner SW. Genetic predictors of response to therapy in childhood asthma. Mol
Diag Ther 2009;13:127-35.
9. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M. Polymorphism of the
ADRB2 gene and response to inhaled beta-agonists in children with asthma: a
meta-analysis. J Asthma 2009;46:900-5.
10. Turner SW, Khoo SK, Laing IA, Palmer LJ, Gibson NA, Rye P, et al. beta2 adre-
noceptor Arg16Gly polymorphism, airway responsiveness, lung function and
asthma in infants and children. Clin Exp Allergy 2004;34:1043-8.
11. Carroll CL, Stoltz P, Schramm CM, Zucker AR. Beta2-adrenergic receptor poly-
morphisms affect response to treatment in children with severe asthma exacerba-
tions. Chest 2009;135:1186-92.
12. Carroll CL, Sala KA, Zucker AR, Schramm CM. Beta-adrenergic receptor poly-
morphisms associated with length of ICU stay in pediatric status asthmaticus. Pe-
diatr Pulmonol 2012;47:233-9.
13. Carroll CL, Sala KA, Zucker AR, Schramm CM. beta2-adrenergic receptor haplo-
type linked to intubation and mechanical ventilation in children with asthma.
J Asthma 2012;49:563-8.
14. Giubergia V, Gravina L, Castanos C, Chertkoff L. Influence of beta(2)-adrenergic
receptor polymorphisms on asthma exacerbation in children with severe asthma
regularly receiving salmeterol. Ann Allergy Asthma Immunol 2013;110:156-60.
15. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, et al.
Tailored second-line therapy in asthmatic children with the arg(16) genotype. Clin
Sci 2013;124:521-8.
16. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M.
Effect of ADRB2 polymorphisms on response to long acting beta2-agonist ther-
apy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370:
2118-25.
17. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, et al. Beta2-
receptor polymorphisms in patients receiving salmeterol with or without flutica-
sone propionate. Am J Respir Crit Care Med 2010;181:676-87.
18. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun
WJ, et al. National Heart, Lung and Blood Institute’s Asthma Clinical Research
Network. Effect of beta2-adrenergic receptor polymorphism on response to long
acting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised,
placebo-controlled, crossover trial. Lancet 2009;374:1754-64.
19. Vijverberg SJ, Koster ES, Tavendale R, Leusink M, Koenderman L, Raaijmakers
JA, et al. ST13 polymorphisms and their effect on exacerbations in steroid-
treated asthmatic children and young adults. Clin Exp Allergy 2015;45:1051-9.
20. Galanter JM, Gignoux CR, Torgerson DG, Roth LA, Eng C, Oh SS, et al. Genome-
wide association study and admixture mapping identify different asthma-associated
loci in Latinos: the Genes-Environments and Admixture in Latino Americans
study. J Allergy Clin Immunol 2014;134:295-305.21. Magi R, Morris AP. GWAMA: software for genome-wide association meta-anal-
ysis. BMC Bioinformatics 2010;11:288.
22. Purcell S, Cherny SS, Sham PC. Genetic power calculator: Design of linkage and
association genetic mapping studies of complex traits. Bioinformatics 2003;19:
149-50.
23. Hall IP, Blakey JD. Genetic association studies in thorax. Thorax 2005;60:357-9.
24. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on
defining genetic profiles for personalized medicine. J Allergy Clin Immunol
2014;133:16-26.
25. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of
genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodi-
lator pharmacodynamics. Clin Pharmacol Ther 1999;65:519-25.
26. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, et al. Pharmacogenetic
differences in response to albuterol between Puerto Ricans and Mexicans with
asthma. Am J Respir Crit Care Med 2005;171:563-70.
27. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM,
et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the
response to regular use of albuterol in asthma. Am J Respir Crit Care Med
2000;162:75-80.
28. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Na-
tional Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. Use
of regularly scheduled albuterol treatment in asthma: Genotype-stratified, rando-
mised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12.
29. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma
exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor
polymorphism. Thorax 2000;55:762-7.
30. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta2-
adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in
patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004;57:
68-75.
31. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British
guideline on the management of asthma 2014. Available at: https://www.brit-
thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guide
line-2014/. Accessed June 2, 2015.
32. Global Initiative for Asthma. Pocket guide for asthma management and prevention.
Available at: http://www.ginasthma.org/documents/1. Accessed June 2, 2015.
33. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP,
Hop WC, et al. Combination therapy salmeterol/fluticasone versus doubling dose
of fluticasone in children with asthma. Am J Respir Crit Care Med 2010;182:
1221-7.
34. Lipworth B. Beta-adrenoceptor genotype and bronchoprotective subsensitivity with
long-acting beta-agonists in asthma. Am J Respir Crit Care Med 2013;188:1386-7.
35. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic
receptor genotypes on signal transduction in human airway smooth muscle cells.
Am J Respir Cell Mol Biol 1995;13:25-33.
36. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on
surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am
J Respir Crit Care Med 2003;167:1232-8.
37. Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, et al.
Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom con-
trol during longacting beta agonist treatment in a multiethnic asthma population: a
genetic study. Lancet Respir Med 2014;2:204-13.
38. Turner S, Thomas M, von Ziegenweidt J, Price D. Prescribing trends in asthma: a
longitudinal observational study. Arch Dis Child 2009;94:16-22.
39. Lozano P, Fishman P, VonKorff M, Hecht J. Health care utilization and cost among
children with asthma who were enrolled in a health maintenance organization. Pe-
diatrics 1997;99:757-64.
40. Wang LY, Zhong Y, Wheeler L. Direct and indirect costs of asthma in school-age
children. Prevent Chronic Dis 2005;2:A11.
41. Lenney W. The burden of pediatric asthma. Pediatr Pulmonol 1997;15:13-6.
42. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetic effect of
ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to
inhaled combination therapy. J Clin Pharm Ther 2011;36:399-405.
REFERENCES
E1. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S.
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young
asthmatics taking regular salmeterol. Thorax 2006;61:940-4.
E2. Nishimura KK, Galanter JM, Roth LA, Oh SS, Thakur N, Nguyen EA, et al.
Early-life air pollution and asthma risk in minority children. The GALA II and
SAGE II studies. Am J Respir Crit Care Med 2013;188:309-18.
E3. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in
unrelated individuals. Genome Res 2009;19:1655-64.
E4. Turner SW, Ayres JG, Macfarlane TV, Mehta A, Mehta G, Palmer CN, et al. A
methodology to establish a database to study gene environment interactions for
childhood asthma. BMC Med Res Methodol 2010;10:107.
E5. Koster ES, Raaijmakers JA, Koppelman GH, Postma DS, van der Ent CK, Koen-
derman L, et al. Pharmacogenetics of anti-inflammatory treatment in children
with asthma: rationale and design of the PACMAN cohort. Pharmacogenomics
2009;10:1351-61.
E6. Hawcutt DB, Jorgensen AL, Wallin N, Thompson B, Peak M, Lacy D, et al. Ad-
renal responses to a low dose short synacthen test in children with asthma. Clin
Endocrinol (Oxf) 2015;82:648-56.
J ALLERGY CLIN IMMUNOL
nnn 2016
7.e1 TURNER ET ALMETHODS
BREATHE study
The BREATHE study is cohort of children and young adults with doctor-
diagnosed asthma recruited from primary and secondary care in Tayside.
Details of enrollment have been presented in detail previously.E1 Subjects
aged more than 18 years were excluded from the present analysis.
GALA II study
The Genes-Environment and Admixture in Latino Americans (GALA II)
study is a multicenter study of children and young adults with and without
asthma and has been fully described previously.E2 Eligibility criteria were as
follows: age of 8 to 21 years, all 4 grandparents were Latino, and smoking his-
tory was less than 10 pack years. Asthma was defined based on a physician’s
diagnosis and report of symptoms and medication use within the last 2 years.
Subjects aged more than 18 years and without asthmawere excluded from this
analysis. Estimates of African, European, and Native American ancestries
were obtained by using an unsupervised analysis in ADMIXTURE,E3
assuming 3 ancestral populations: African, European, and Native American.
We used reference haplotypes from subjects from HapMap phase II (http://
hapmap.ncbi.nlm.nih.gov) for the European and African components: Utah
residents with Northern and Western European ancestry from the CEPH
collection (CEU) and Yoruba in Ibadan, Nigeria (YRI). The Native American
reference population consisted of 71 Native American subjects genotyped at
the University of California San Francisco on the Axiom LAT1 array,
including 14 Zapotec, 2 Mixe, and 11 Mixtec from the southern State of
Oaxaca and 44 Nahua subjects from Central Mexico.
PAGES
PAGES (http://www.asthma-pages.com/) was designed to explore interac-
tions between genetic variations and exposures (including medications) in
children with asthma. Children were recruited from primary and secondary
care. Details of recruitment have been published previously.E4 Ethnicity was
not identified for the initial recruits to the study but was captured for approx-
imately half participants and categorized as African, Chinese, Indian, Mixed,
Pakistani, White British, or other.PACMAN cohort
PACMAN is a study of children aged 4 to 12 years recruited through
community pharmacies in TheNetherlands between 2009 and 2012. Details of
the study protocol have been described elsewhere.E5 A detailed history of the
subjects was obtained, including information on asthma symptoms, exacerba-
tions, and medication use over the preceding 12 months during a study visit in
the community pharmacies. Ethnicity was categorized as African, Asian,
white (Dutch, Turkish, or Moroccan), Hispanic, or mixed.
PASS
PASS is a cohort study designed to explore the clinical and pharmaco-
genomics associations between use of corticosteroids in children with
asthma and adrenal suppression. Assessment included a respiratory ques-
tionnaire and collection of blood or salvia for DNA extraction. Details of
recruitment have been published previously.E6 Children with Asian ancestry
were excluded, and ethnicity for those recruited was categorized as African,
white, or other.
TABLE E1. Power of the sample size of the 5 cohorts combined
to detect increases in ORs for asthma exacerbations
Treatment group OR 5 1.2 OR 5 1.5 OR 5 3
SABA alone 44% 96% 100%
ICS 70% 99% 100%
ICS1LABA 36% 91% 100%
ICS1LTRA 20% 64% 100%
ICS1LABA1LTRA 34% 89% 100%
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TABLE E2. OR for exacerbation regardless of treatment in each cohort from the additive model
BREATHE GALA II PACMAN PAGES PASS Pooled
OR (95% CI) 1.14 (0.97-1.34),
n 5 1210
1.18 (0.98-1.41),
n 5 1171
1.00 (0.69-1.41),
n 5 760
1.02 (0.82-1.28),
n 5 695
1.08 (0.81-1.43),
n 5 390
1.11 (1.01-1.22)
The OR indicates the risk for each A allele of rs1042713. The logistic regression models adjusted for age, sex, and exposure to cigarette smoke. The P value for the pooled analysis
was .035.
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TABLE E3. OR and 95% CI for exacerbation for each Arg16 allele compared with Gly 16 homozygotes among children receiving a
daily SABA regardless of other treatment
BREATHE PACMAN PAGES Pooled
OR (95% CI) for children
in receipt of SABA every day
1.13 (0.77-1.65), n 5 250 1.41 (0.83-2.40), n 5 364 0.69 (0.44-1.10), n 5 208 1.01 (0.79-1.31)
The logistic regression models adjusted for sex, age, and exposure to cigarette smoke. The P value for the pooled analysis was .91.
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TABLE E4. OR and 95% CI for exacerbation by using the additive model (ie, risk for each Arg16 allele compared with none) among
children treated with ICSs and LABAs for the 3 populations in which SABA use was determined
BREATHE PACMAN PAGES Pooled
OR (95% CI) for children in
receipt of SABA every day
1.02 (0.37-2.81), n 5 44 4.57 (1.40-14.89), n 5 74 0.89 (0.30-2.63), n 5 47 1.49 (0.79-2.79)
OR (95% CI) for children in
receipt of SABA less than once a day
1.71 (0.94-3.12), n 5 94 0.65 (0.06-19.51), n 5 72 1.55 (0.80-2.99), n 5 87 1.59 (1.03-2.45)
The logistic regression models adjusted for sex, age, and exposure to cigarette smoke. The P values for the pooled analysis were .22 and .038.
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